Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;4(6):1181-91.
doi: 10.2147/ndt.s3238.

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Bernhard T Baune  1
Affiliations

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Bernhard T Baune. Neuropsychiatr Dis Treat. 2008 Dec.

Abstract

Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.

Keywords: adverse effects; general anxiety disorder; major depressive disorders; quetiapine; randomized controlled studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Improvement of quality of life measures in patients with generalized anxiety disorder.
See this image and copyright information in PMC

References

    1. Alexiadis M, Whitehorn D, Woodley H, et al. Prolactin elevation with quetiapine. Am J Psychiatry. 2002;159:1608–9. - PubMed
    1. Ananth J. Treatment-resistant depression. Psychother Psychosom. 1998;67:61–70. - PubMed
    1. Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol. 2005;20:237–41. - PubMed
    1. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33:562–5. - PubMed
    1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–6. - PubMed

LinkOut - more resources